Breakthrough Therapy Designation granted based on key positive data from the Phase 2b (RIZE) study and current unmet medical need in congenital hyperinsulinism (HI) Ersodetug continues to advance in ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback